Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C37454
http://purl.obolibrary.org/obo/NCIT_C37454
|
|---|---|
| Preferred Name | Cenersen |
| Definitions |
A phosphorothioate oligonucleotide harboring nucleotide sequences complementary to tumor suppressor p53 mRNA. Cenersen hybridizes with p53 mRNA molecules, and induces Rnase H dependent hydrolysis of p53 transcripts in the double stranded section of the hybrids, thereby resulting in loss of p53 production. Loss of p53 activity leads to sensitization of cancer cells to other therapeutics.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A phosphorothioate oligonucleotide harboring nucleotide sequences complementary to tumor suppressor p53 mRNA. Cenersen hybridizes with p53 mRNA molecules, and induces Rnase H dependent hydrolysis of p53 transcripts in the double stranded section of the hybrids, thereby resulting in loss of p53 production. Loss of p53 activity leads to sensitization of cancer cells to other therapeutics. |
|---|---|
| prefLabel | Cenersen
|
| label | Cenersen
|
| PDQ_Closed_Trial_Search_ID | 354249
|
| code | C37454
|
| Has_Target | |
| prefixIRI | NCIT:C37454
|
| in_subset |
See more
See less
|
| Display_Name | Cenersen
|
| Preferred_Name | Cenersen
|
| FDA_UNII_Code | K6KJ8AZ05F
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Cenersen
|
| CAS_Registry | 415168-49-9
|
| NCI_Drug_Dictionary_ID | 354249
|
| Legacy Concept Name | EL625
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 354249
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C0700610
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |